期刊文献+

心血管疾病的精准医疗实践与思考 被引量:2

原文传递
导出
摘要 自美国总统奥巴马在2015年国情咨文演讲中提出了“精准医疗计划”(precision medicine initiative)后,精准医疗已成为眼下医学界最受关注和热议的时代概念。该计划致力于治愈癌症和糖尿病等疾病,目的是加快在基因组层面对疾病的精准认识和针对性治疗。精准医疗是以个体化医疗为基础,基因组学、蛋白质学、生物信息学及大数据科学等多学科交叉应用而发展起来的新型医学诊疗模式。
作者 潘博 田杰
出处 《中华儿科杂志》 CAS CSCD 北大核心 2016年第4期244-245,共2页 Chinese Journal of Pediatrics
  • 相关文献

参考文献10

  • 1Fahed AC, Gelb BD, Seidman JG, et al. Genetics of congenital heart disease : the glass half empty [ J ]. Circ Res, 2013,112 ( 4 ) : 707-720. DOI: 10. ll61/CIRCRESAHA. 112. 300853.
  • 2Graham IM, Daly LE, Refeum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project[ J]. JAMA, 1997, 277(22) :1775-1781.
  • 3Yong H, Jianping L, Xianhui Q, et al. Efficacy of folio acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial [ J ]. Jama, 2015, 313 (13) : 1325-1335. DOI : 10. 1001/jama. 2015. 2274.
  • 4Rowley AH. Kawasaki disease: novel insights into etiology and genetiesusceptibility [ J ]. Annu Rev Med, 2011,62 : 69-77. DOI : 10.1146/annurev-med-042409-151944.
  • 5Kong Y, Tannous P, Lu G, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy [ J]. Circulation ,2006,113 (22) :2579-2588.
  • 6Zhang CL, Mckinsey TA, Chang S, et al. Class II histone deacetyiases act as signal-responsive repressors of cardiac hypertrophy[ J]. Cell,2002,110(4) : 479-488.
  • 7Hedley PL, J0rgensen P, Sehlamowitz S, et al. The genetic basis of long QT and short QT syndromes : a mutation update[ J ]. Hum Mutat,2009,30(ll) :1486-1511. DOI: 10. 1002/humu. 21106.
  • 8卢颖如,胡大一.遗传性QT延长综合征的遗传学类型与临床治疗[J].国外医学(心血管疾病分册),2002,29(5):276-278. 被引量:2
  • 9Lin J, Jin H, Du J. Assessment of therapeutic biomarkers in the treatment of children with postural tachycardia syndrome and vasovagal syncope [ J ]. Cardiol Young, 2014,24 ( 5 ) : 792-796. DOI : 10. 1017/S1047951114000316.
  • 10黄盛文,向道康,吴海丽,陈保林,安邦权,李贵芳.五种基因多态性对华法林用量个体差异影响的研究[J].中华医学遗传学杂志,2011,28(6):661-665. 被引量:20

二级参考文献33

  • 1Yu HC, Chan TY, Critchely JA, et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJM, 1996, 89:127-135.
  • 2Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population. Ann Pharmacother, 2000, 34 : 1395-1401.
  • 3Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J, 2003, 3: 202-214.
  • 4Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 5Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005,106 : 2329-2933.
  • 6Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics, 2009, 19: 226-234.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta, 2004,348:57-61.
  • 9Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmaeogenomics J, 2005, 5: 262-270.
  • 10Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet, 2007,121:23-34.

共引文献20

同被引文献15

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部